Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : SARS - what next? -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (372)	5/2/2003 5:38:02 PM
From: Ilaine	Read Replies (1) \| Respond to of 1070

Hmm. Genetic immunity is a fascinating concept. I see that people who are homozygous for CCR5-delta 32 (whatever that is) don't come down with AIDS, while those who are heterozygous for CCR5-delta 32 have delayed disease progress. It may also give immunity to the Black Death. 10%-15% of Europeans are heterozygous for CCR5-delta 32, 1% are homozygous, and only 2% carry the gene at all in central Asia. The mutation is completely absent among East Asians, Africans, and American Indians. cdc.gov hivandhepatitis.com student.biology.arizona.edu science-frontiers.com BTW, I just missed the chance to be a guinea pig in CD32 genomic research on rheumatoid arthritis at the University of Pittsburgh but am going to take part in a study of RA and vascular diseases. Free heart scan, free doppler scan of my carotid, no drugs. Whee!